Business Daily from THE HINDU group of publications
Wednesday, May 30, 2007
ePaper
Business Daily from THE HINDU group of publications Wednesday, May 30, 2007 ePaper |
|
|
|
|
|
|
|
Corporate
-
Courts/Legal Issues Marketing - New Products & Services Industry & Economy - Pharmaceuticals
Our Bureau,
New Delhi May 29 Ranbaxy Laboratories has said that the Norwegian Appeals Court has ruled in its favour in its case against Pfizer over the cholesterol drug, atorvastatin. In a statement, the company said that the Oslo City Court had also previously found that the Gurgaon-based company had not infringed on two of Pfizer's Norwegian patents for Lipitor. The court had, however, denied Ranbaxy's assertion of non-infringement on a third patent. Ranbaxy said that in today's decision, the appeal court upheld the city court ruling with regards to the first two patents, and overturned the adverse ruling on the third. This clears the way for Ranbaxy to market atorvastatin tablets in Norway, said the company. "This is a most important decision for Ranbaxy as it completely validates our position in relation to the Atorvastatin patents," said Mr Jay Deshmukh, Senior Vice-President, Global Intellectual Property. However, Pfizer plans to appeal against the ruling. Lipitor generated almost $13 billion in 2006 sales for the New York-based company, the world's biggest drugmaker. Its Lipitor patent is set to expire in the US in 2010. Ranbaxy and Pfizer have patent challenge cases over the drug being heard in courts across the world.
More Stories on : Courts/Legal Issues | New Products & Services | Pharmaceuticals | IPR | Ranbaxy Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|